Previous studies showed that in a murine model of ARDS, genetic deletion or pharmacological inhibition of NLRP3 significantly attenuated lung injury and improved survival rates, highlighting the importance of NLRP3 as a potential therapeutic target [9,10]. The gene discussed is NLRP3; the disease is acute respiratory distress syndrome.